Skip to content Home / Companies / CUE CUE
Cue Biopharma, Inc. (CUE) XNAS PHARMACEUTICAL PREPARATIONS Net insider selling (90d)
Latest CUE Insider Trades
About Cue Biopharma, Inc. (CUE) Cue Biopharma Inc is a clinical-stage therapeutics company focused on advancing a robust portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its product pipeline includes CUE-221, an anti-IgE antibody candidate being developed for allergic diseases. The company has also developed the Immuno-STAT platform for targeting disease-related T cells and is developing CUE-401, an IL-2 and TGF-B therapeutic candidate for autoimmune diseases.
Headquarters BOSTON, MA
Employees 29
Listed 2018
Exchange XNAS https://www.cuebiopharma.com SEC filings for CUE on EDGAR
90-Day SEC Filing Activity Form 4 transaction type Transactions Shares Total value Open-market sale 11 72,715 $2.04M Grant or award 18 1,277,995 Option exercise 6 282,044
CUE Insider Transactions (Form 4) 57 36 Form 4 filings on record, the earliest from Nov 29, 2024, newest first. Filing history page 1 of 2.
Date Insider Transaction Security Shares Price Value Jul 9, 2026 PS Pasha Sarraf - Director Grant or award Common Stock 18,400
Recent CUE Form 8-K Filings 5
Recent CUE Form 144 Notices of Proposed Sale 2 A Form 144 is notice of an INTENDED sale, not a completed one. It often precedes the Form 4 that reports the trade actually happening.
Filed Filer Relationship Shares Market value Notice Aug 14, 2026 Shao-Lee Lin Officer, Director 40,000 $1.08M View on EDGAR Aug 13, 2026 Sumita Ray Officer, CORPORATE SECRETARY
CUE Insider Trading - FAQ
What is the latest insider trade for CUE? Cue Biopharma, Inc. (CUE) had 15 insider filings in the last 90 days, with the most recent on 2026-08-28. The full record for CUE runs to 36 Form 4 filings, the earliest from 2024-11-29. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
How many insiders are buying CUE stock? No insider purchases of CUE were filed in the last 90 days. 8 purchases are on record for this company.
How many insiders are selling CUE stock? 11 insider sales of CUE were filed in the last 90 days, totaling $2.04M.
Where can I see CUE SEC filings (Form 4, 10-K, 10-Q, 8-K)? This page tracks CUE Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
How can I follow CUE insider buys? Create a free InsiderAlpha account and press Watch on this page to add CUE to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
More Health Care Companies with Insider Activity Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Related Companies - Recent Insider Activity What is SEC Form 4? The filing insiders must submit within two business days of a trade, and how to read its transaction codes. Track CUE insider activity as it files Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
Sign up free
Market cap $248.23M
P/E ratio -
Dividend yield -
Average volume 164.3K
52 week high $45.50
52 week low $4.97
Today's high -
Today's low -
Open -
Volume -
Previous close $37.84
Shares outstanding 7.26M Market cap
$248.23M
29 employees
CUE Insider Sentiment - Last 90 Days Share of open-market insider dollar volume that was buying versus selling, from SEC Form 4 filings.
0% Buying 100% Selling
0 insider purchases totaling $0 against 11 sales totaling $2.04M.
Most-Active CUE Insiders - Last 90 Days 10 Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
Jul 9, 2026 PG Pamela Garzone - Director Grant or award Common Stock 18,900 $0.00 -
Aug 13, 2026 SR Sumita Ray - Officer Option exercise Common Stock 18,196 $0.00 -
Aug 13, 2026 SR Sumita Ray - Officer Open-market sale Common Stock 2,383 $29.37 $70K
Aug 13, 2026 SR Sumita Ray - Officer Open-market sale Common Stock 6,442 $30.35 $196K
Aug 13, 2026 SR Sumita Ray - Officer Open-market sale Common Stock 4 $31.13 $125
Aug 13, 2026 SR Sumita Ray - Officer Option exercise Common Stock 18,196 $0.00 -
Aug 12, 2026 SL Shao-Lee Lin - Officer Option exercise Common Stock 109,179 $0.00 -
Aug 12, 2026 SL Shao-Lee Lin - Officer Open-market sale Common Stock 34,225 $26.99 $924K
Aug 12, 2026 SL Shao-Lee Lin - Officer Open-market sale Common Stock 5,775 $27.75 $160K
Aug 13, 2026 SL Shao-Lee Lin - Officer Open-market sale Common Stock 5,423 $27.19 $147K
Aug 13, 2026 SL Shao-Lee Lin - Officer Open-market sale Common Stock 2,375 $28.11 $67K
Aug 13, 2026 SL Shao-Lee Lin - Officer Open-market sale Common Stock 10,460 $29.48 $308K
Aug 12, 2026 SL Shao-Lee Lin - Officer Option exercise Common Stock 109,179 $0.00 -
Jul 30, 2026 JA James M. Ahlers - Officer Grant or award Common Stock 25,500 $0.00 -
Jul 30, 2026 JA James M. Ahlers - Officer Grant or award Stock Option (Right to Buy) 51,000 $0.00 -
Jun 1, 2026 SL Shao-Lee Lin - Officer Grant or award Pre-Funded Warrants (Right to Buy) 90,906 $11.00 $1.00M
Jun 1, 2026 SL Shao-Lee Lin - Officer Grant or award Common Stock Warrants (Right to Buy) 45,453 - -
Jul 9, 2026 PS Pasha Sarraf Grant or award Common Stock 21,800 $0.00 -
Jul 9, 2026 SR Sumita Ray - Officer Grant or award Common Stock 54,589 $0.00 -
Jul 9, 2026 SR Sumita Ray - Officer Grant or award Common Stock 54,589 $0.00 -
Jul 9, 2026 SL Shao-Lee Lin - Officer Grant or award Common Stock 327,537 $0.00 -
Jul 9, 2026 SL Shao-Lee Lin - Officer Grant or award Common Stock 327,537 $0.00 -
Jun 1, 2026 SL Shao-Lee Lin - Officer Open-market purchase Pre-Funded Warrants (Right to Buy) 90,906 $11.00 $1.00M
Jun 1, 2026 SL Shao-Lee Lin - Officer Open-market purchase Common Stock Warrants (Right to Buy) 45,453 - -
May 3, 2026 SL Shao-Lee Lin - Officer Grant or award Common Stock 327,537 $0.00 -
May 3, 2026 SL Shao-Lee Lin - Officer Grant or award Stock Option (right to buy) 655,074 $0.00 -
Apr 9, 2026 CS Colin Sandercock - Officer Grant or award Stock Option (right to buy) 200,000 $0.00 -
Apr 9, 2026 LW Lucinda Warren - Officer Grant or award Stock Option (right to buy) 250,000 $0.00 -
Apr 9, 2026 DB Daniel G. Baker - Officer Grant or award Stock Option (right to buy) 100,000 $0.00 -
Jan 2, 2026 PK Peter A. Kiener Grant or award Stock Option (right to buy) 24,400 $0.00 -
Jan 2, 2026 PG Pamela Garzone Grant or award Stock Option (right to buy) 24,400 $0.00 -
Jan 2, 2026 FM Frank Morich Grant or award Stock Option (right to buy) 24,400 $0.00 -
Jan 2, 2026 PV Patrick Verheyen Grant or award Stock Option (right to buy) 24,400 $0.00 -
Jan 2, 2026 PS Pasha Sarraf Grant or award Stock Option (right to buy) 24,400 $0.00 -
Dec 30, 2025 PS Pasha Sarraf Open-market purchase Common Stock 4,229 $9.28 $1K
Dec 30, 2025 PS Pasha Sarraf Open-market purchase Common Stock 77,148 $9.01 $23K
Dec 30, 2025 PS Pasha Sarraf Open-market purchase Common Stock 86,947 $9.52 $28K
Dec 30, 2025 PS Pasha Sarraf Open-market purchase Common Stock 78,116 $9.34 $24K
Dec 30, 2025 PS Pasha Sarraf Open-market purchase Common Stock 77,417 $9.05 $23K
Sep 26, 2025 CS Colin Sandercock - Officer Grant or award Stock Option (right to buy) 30,000 $0.00 -
Dec 3, 2025 CS Colin Sandercock - Officer Grant or award Stock Option (right to buy) 70,000 $0.00 -
$CYAN
CYANOTECH CORP
